Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

GCC Structural Heart Devices Market

ID: MRFR/MED/55139-HCR
200 Pages
Satyendra Maurya
April 2026

GCC Structural Heart Devices Market Research Report: By Type (Heart Valve Devices, Annuloplasty Rings, Occluders, Delivery Systems), By Indication (Valvular Heart Disease, Cardiomyopathy) andBy Procedure (Replacement Procedures, Repair Procedures) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

GCC Structural Heart Devices Market Infographic
Purchase Options

GCC Structural Heart Devices Market Summary

As per Market Research Future analysis, the GCC structural heart devices market size was estimated at 19.25 $ Million in 2024. The GCC structural heart-devices market is projected to grow from 20.54 $ Million in 2025 to 39.36 $ Million by 2035, exhibiting a compound annual growth rate (CAGR) of 6.7% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The GCC structural heart devices market is poised for substantial growth driven by technological advancements and increasing patient awareness.

  • Technological advancements in device design are enhancing the efficacy and safety of structural heart devices.
  • The largest segment in the GCC market is expected to be transcatheter heart valves, while the fastest-growing segment is likely to be left atrial appendage closure devices.
  • Regulatory support is fostering innovation and expediting the approval process for new devices in the region.
  • Rising incidence of cardiovascular diseases and an aging population are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 19.25 (USD Million)
2035 Market Size 39.36 (USD Million)
CAGR (2025 - 2035) 6.72%

Major Players

Edwards Lifesciences (US), Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), Cardinal Health (US), LivaNova (GB), Terumo Corporation (JP), JenaValve Technology (DE), AtriCure (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

GCC Structural Heart Devices Market Trends

The structural heart devices market is currently experiencing notable growth, driven by advancements in technology and increasing awareness of heart diseases. In the GCC region, healthcare systems are evolving, with a focus on enhancing patient outcomes through innovative medical devices. The rising prevalence of cardiovascular conditions has prompted healthcare providers to adopt advanced solutions, thereby expanding the market. Furthermore, government initiatives aimed at improving healthcare infrastructure and access to cutting-edge treatments are likely to bolster the adoption of structural heart devices. In addition, the collaboration between medical device manufacturers and healthcare institutions appears to be fostering an environment conducive to research and development. This synergy may lead to the introduction of novel products tailored to meet the specific needs of patients in the region. As the population ages and lifestyle-related health issues become more prevalent, the demand for effective structural heart solutions is expected to rise. Overall, the structural heart-devices market is poised for continued expansion, reflecting the commitment of stakeholders to enhance cardiovascular care in the GCC region.

Technological Advancements

The structural heart-devices market is witnessing rapid technological innovations, including minimally invasive procedures and advanced imaging techniques. These developments are enhancing the precision and effectiveness of treatments, thereby attracting more healthcare providers to adopt these solutions.

Regulatory Support

Regulatory bodies in the GCC are increasingly supportive of new medical technologies, streamlining approval processes for innovative devices. This regulatory environment is likely to encourage manufacturers to invest in research and development, leading to a wider array of options for healthcare professionals.

Growing Patient Awareness

There is a noticeable increase in patient awareness regarding heart health and available treatment options. Educational campaigns and community outreach programs are contributing to this trend, which may drive demand for structural heart devices as patients seek effective solutions for their conditions.

GCC Structural Heart Devices Market Drivers

Aging Population

The demographic shift towards an aging population in the GCC region is a notable driver for the structural heart devices market. As life expectancy increases, the incidence of age-related cardiovascular conditions is also rising. This demographic trend necessitates the development and deployment of advanced medical devices tailored to the needs of older patients. The structural heart-devices market is poised to benefit from this shift, as healthcare providers seek effective solutions to manage the complexities associated with aging. It is estimated that by 2030, the proportion of individuals aged 60 and above in the GCC will increase significantly, further amplifying the demand for specialized heart devices. This evolving demographic landscape suggests a sustained growth potential for the market.

Investment in Healthcare Infrastructure

The GCC countries are witnessing substantial investments in healthcare infrastructure, which is a crucial driver for the structural heart devices market. Governments are prioritizing healthcare as part of their national development plans, leading to the establishment of advanced medical facilities and specialized centers. This investment is expected to enhance the accessibility and quality of healthcare services, thereby increasing the adoption of structural heart devices. For instance, the healthcare expenditure in the GCC is projected to reach approximately $100 billion by 2025, indicating a strong commitment to improving health outcomes. As more hospitals are equipped with cutting-edge technology, the structural heart-devices market is likely to experience significant growth, driven by the demand for innovative treatment options.

Increased Focus on Preventive Healthcare

There is a growing emphasis on preventive healthcare in the GCC, which serves as a significant driver for the structural heart devices market. As awareness of cardiovascular health increases, more individuals are seeking early interventions and screenings. This shift towards preventive measures is likely to result in higher demand for structural heart devices, as healthcare systems aim to address issues before they escalate. The structural heart-devices market may benefit from initiatives promoting regular health check-ups and lifestyle modifications, which can lead to earlier diagnoses and treatments. Consequently, the market is expected to expand as healthcare providers adapt to this proactive approach, integrating advanced devices into their preventive care strategies.

Technological Innovations in Device Design

Technological innovations in the design and functionality of structural heart devices are driving the market forward. The introduction of minimally invasive procedures and advanced materials has revolutionized treatment options for patients with structural heart issues. These innovations not only improve patient outcomes but also reduce recovery times, making them more appealing to both healthcare providers and patients. The structural heart devices market is likely to see a surge in demand as new technologies emerge, offering enhanced performance and safety. Furthermore, ongoing research and development efforts in the GCC are expected to yield novel devices that cater to specific patient needs, thereby expanding the market's potential.

Rising Incidence of Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases in the GCC region is a primary driver for the structural heart devices market. As lifestyle-related health issues become more common, the demand for innovative treatment options rises. Reports indicate that cardiovascular diseases account for a significant portion of mortality rates in the region, prompting healthcare providers to seek advanced solutions. The structural heart-devices market is expected to grow as hospitals and clinics invest in state-of-the-art technologies to address these health challenges. Furthermore, the GCC governments are likely to allocate more resources towards healthcare infrastructure, enhancing the availability of these devices. This trend suggests a robust growth trajectory for the market, as the need for effective interventions becomes increasingly urgent.

Market Segment Insights

By Type: Transcatheter Aortic Valve Replacement (Largest) vs. Mitral Valve Repair Devices (Fastest-Growing)

The GCC structural heart-devices market displays a segmented structure with Transcatheter Aortic Valve Replacement (TAVR) holding the largest market share due to its established position and increasing adoption rates among healthcare providers. In contrast, Mitral Valve Repair Devices are rapidly gaining traction, driven by advancements in technology and rising awareness of minimally invasive surgical options. The growth trends within this segment are largely influenced by factors such as the aging population and an increase in cardiovascular diseases. As more healthcare facilities adopt innovative treatment solutions, the demand for Left Atrial Appendage Closure Devices and Transcatheter Pulmonary Valve options is also expected to rise, reflecting a dynamic and competitive market environment focused on enhancing patient outcomes.

Transcatheter Aortic Valve Replacement (Dominant) vs. Mitral Valve Repair Devices (Emerging)

Transcatheter Aortic Valve Replacement (TAVR) remains the dominant force within the GCC structural heart-devices market, characterized by its established efficacy in treating severe aortic stenosis. With continued improvements in procedural techniques and device designs, TAVR is preferred for its minimally invasive nature, affording shorter recovery times and reduced hospital stays. In contrast, Mitral Valve Repair Devices are emerging as a vital segment due to innovative product developments and increasing clinical trials supporting their use. These devices offer effective solutions for mitral regurgitation, leveraging cutting-edge technology that resonates with the growing preference for less invasive surgical interventions while also being supported by expanding reimbursement frameworks.

By Procedure Type: Minimally Invasive (Largest) vs. Surgical (Fastest-Growing)

In the GCC structural heart-devices market, the distribution of market share among the procedure types is characterized by a significant dominance of minimally invasive techniques, which are favored for their reduced recovery times and lower risk of complications. Surgical interventions follow, but their growth is being outpaced by percutaneous procedures, which are becoming increasingly popular due to advancements in technology that enhance their safety and efficacy. The growth trends within this segment are being driven by several factors, including an increasing prevalence of structural heart diseases, a rise in the aging population, and continual innovations in device technology. As healthcare providers increasingly focus on patient-centric care, the demand for minimally invasive and percutaneous procedures is expected to surge, positioning them as critical components in the evolving landscape of the GCC structural heart-devices market.

Minimally Invasive (Dominant) vs. Surgical (Emerging)

Minimally invasive procedures are leading the way in the GCC structural heart-devices market due to their numerous advantages, including shorter hospital stays, minimal scarring, and quicker recovery for patients. These techniques are widely accepted among both healthcare professionals and patients, which contributes to their dominant market position. In contrast, surgical procedures, while traditionally seen as the standard approach for many heart conditions, are now regarded as emerging due to the growing interest in less invasive options. With evolving technology and training, surgical procedures are expected to adapt, improving their efficacy and safety, thus making them more competitive in the marketplace.

By Indication: Aortic Stenosis (Largest) vs. Mitral Regurgitation (Fastest-Growing)

In the GCC structural heart-devices market, Aortic Stenosis dominates with the largest market share, exploiting the increasing prevalence of this condition in the region. Mitral Regurgitation has gained attention as the fastest-growing segment. The rising incidence of valvular heart diseases and advancements in treatment options are further influencing this market distribution. Growth trends indicate a significant uptick in the adoption of innovative therapies and devices for heart valve conditions. The GCC region is witnessing increased healthcare expenditure, and this is facilitated by a greater focus on early diagnosis and treatment protocols. Factors such as lifestyle changes, aging populations, and heightened awareness among clinicians are driving the demand for structural heart devices, particularly in the Mitral Regurgitation segment.

Aortic Stenosis (Dominant) vs. Heart Failure (Emerging)

Aortic Stenosis is firmly entrenched as the dominant segment in the GCC structural heart-devices market, characterized by robust treatment pathways and a well-established body of clinical research. Patients suffering from Aortic Stenosis typically require timely interventions to prevent severe complications, creating a steady demand for valve replacement devices. Conversely, Heart Failure, while currently considered an emerging segment, shows significant potential for growth due to rising patient awareness and a shift towards comprehensive heart failure management solutions. Innovations in device technology, enhanced patient monitoring, and integrated care approaches are set to redefine treatment modalities in Heart Failure, paving the way for increased market share in the coming years.

By End User: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

In the GCC structural heart-devices market, hospitals represent the largest segment, commanding a significant portion of the market share due to their comprehensive facilities and specialized care. Ambulatory surgical centers, while smaller in comparison, are rapidly gaining traction, appealing to a demographic that values efficiency and lower costs. The cardiology clinics segment, although vital, is positioned as a niche provider within this landscape, focusing on specialized heart care services. Growth trends in this segment reveal a strong inclination towards minimally invasive procedures, driving the demand for advanced structural heart devices. Factors contributing to this growth include an increasing prevalence of cardiovascular diseases, improved patient awareness, and the expansion of healthcare services in the region. Furthermore, technological advancements and favorable reimbursement policies are enhancing service offerings in hospitals and ambulatory surgical centers, ultimately fostering market expansion.

Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging)

Hospitals dominate the GCC structural heart-devices market as they typically feature comprehensive infrastructure, skilled medical professionals, and a wide array of treatment options. This enables them to cater to a diverse patient population with varying needs. In contrast, ambulatory surgical centers are emerging rapidly due to their cost-effectiveness and focus on outpatient procedures. They provide patients with less invasive surgical options and quicker recovery times, making them increasingly popular. As healthcare shifts towards value-based care, both segments are adapting; hospitals are enhancing their technological capabilities, while ambulatory centers are expanding their service offerings to compete effectively. Ultimately, the collaboration between these segments is essential for advancing patient care in the region.

Get more detailed insights about GCC Structural Heart Devices Market

Key Players and Competitive Insights

The structural heart-devices market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of cardiovascular diseases. Key players such as Edwards Lifesciences (US), Medtronic (US), and Abbott Laboratories (US) are at the forefront, focusing on innovation and strategic partnerships to enhance their market positions. Edwards Lifesciences (US) emphasizes its commitment to research and development, particularly in transcatheter heart valves, which positions it favorably against competitors. Medtronic (US) has adopted a strategy of regional expansion, particularly in emerging markets, while Abbott Laboratories (US) is leveraging its strong portfolio of minimally invasive devices to capture a larger market share. Collectively, these strategies contribute to a competitive environment that is increasingly focused on technological innovation and patient-centric solutions.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for dominance. However, the collective influence of major companies like Boston Scientific (US) and LivaNova (GB) is significant, as they continue to innovate and expand their product offerings. This competitive structure fosters an environment where collaboration and strategic alliances are essential for sustained growth.

In October Boston Scientific (US) announced the launch of its latest transcatheter mitral valve replacement system, which is expected to revolutionize treatment options for patients with mitral valve disease. This strategic move underscores the company's commitment to innovation and positions it as a leader in the structural heart-devices market. The introduction of this advanced technology is likely to enhance patient outcomes and solidify Boston Scientific's competitive edge.

In September LivaNova (GB) entered into a partnership with a leading research institution to develop next-generation heart valve technologies. This collaboration aims to leverage cutting-edge research to accelerate product development and improve clinical outcomes. Such strategic alliances are indicative of the company's focus on innovation and its intent to remain competitive in a rapidly evolving market.

In August Medtronic (US) expanded its manufacturing capabilities in the GCC region, aiming to enhance its supply chain efficiency and reduce lead times for product delivery. This strategic expansion not only strengthens Medtronic's operational capabilities but also reflects its commitment to meeting the growing demand for structural heart devices in the region. The move is expected to bolster the company's market presence and improve its responsiveness to customer needs.

As of November current trends in the structural heart-devices market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in product development. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, advanced technology, and supply chain reliability. This shift suggests that companies that prioritize these aspects will be better positioned to thrive in the future.

Key Companies in the GCC Structural Heart Devices Market include

Industry Developments

The GCC Structural Heart Devices Market has recently seen significant developments, particularly from key players such as Medtronic, Abbott Laboratories, and Boston Scientific. In October 2023, Medtronic announced a partnership with several healthcare institutions across the GCC for the introduction of innovative heart valve therapies, responding to the rising prevalence of cardiovascular diseases in the region. Additionally, Abbott Laboratories revealed advancements in their medical devices aimed at improving patient outcomes, showcasing their continued commitment to Research and Development in the region. 

In terms of mergers and acquisitions, there have been whispers regarding possible acquisition discussions involving Terumo and AtriCure as of September 2023. The market is poised for growth due to increased investments in healthcare infrastructure across the GCC, driven by government initiatives aimed at enhancing health services. The overall market valuation of structural heart devices is projected to rise, reflecting the increasing demand for advanced medical solutions.

Recently, the UAE Ministry of Health and Prevention also indicated an ongoing trend toward the localization of medical manufacturing, which is likely to impact supply chains and the availability of these devices in the region moving forward.

Future Outlook

GCC Structural Heart Devices Market Future Outlook

The Structural Heart Devices Market is projected to grow at a 6.72% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of heart diseases, and rising healthcare expenditure.

New opportunities lie in:

  • Development of minimally invasive surgical techniques for device implantation.
  • Expansion of telehealth services for remote patient monitoring and follow-up.
  • Partnerships with local healthcare providers to enhance distribution networks.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

Market Segmentation

GCC Structural Heart Devices Market Type Outlook

  • Transcatheter Aortic Valve Replacement
  • Mitral Valve Repair Devices
  • Left Atrial Appendage Closure Devices
  • Transcatheter Pulmonary Valve

GCC Structural Heart Devices Market End User Outlook

  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiology Clinics

GCC Structural Heart Devices Market Indication Outlook

  • Aortic Stenosis
  • Mitral Regurgitation
  • Heart Failure
  • Pulmonary Valve Stenosis

GCC Structural Heart Devices Market Procedure Type Outlook

  • Minimally Invasive
  • Surgical
  • Percutaneous

Report Scope

MARKET SIZE 2024 19.25(USD Million)
MARKET SIZE 2025 20.54(USD Million)
MARKET SIZE 2035 39.36(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.72% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Edwards Lifesciences (US), Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), Cardinal Health (US), LivaNova (GB), Terumo Corporation (JP), JenaValve Technology (DE), AtriCure (US)
Segments Covered Type, Procedure Type, Indication, End User
Key Market Opportunities Advancements in minimally invasive procedures enhance growth potential in the structural heart-devices market.
Key Market Dynamics Rising demand for minimally invasive procedures drives innovation in structural heart-devices within the GCC region.
Countries Covered GCC
Author
Author
Author Profile
Satyendra Maurya LinkedIn
Research Analyst
An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.
Co-Author
Co-Author Profile
Garvit Vyas LinkedIn
Vice President - Operations
Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.
Leave a Comment

FAQs

What was the market valuation of the structural heart-devices market in 2024?

The market valuation was $19.25 Million in 2024.

What is the projected market valuation for 2035?

The projected market valuation for 2035 is $39.36 Million.

What is the expected CAGR for the structural heart-devices market during the forecast period 2025 - 2035?

The expected CAGR is 6.72% during the forecast period 2025 - 2035.

Which companies are considered key players in the structural heart-devices market?

Key players include Edwards Lifesciences, Medtronic, Abbott Laboratories, Boston Scientific, and others.

What are the main segments of the structural heart-devices market?

Main segments include Type, Procedure Type, Indication, and End User.

What was the valuation for Transcatheter Aortic Valve Replacement in 2024?

The valuation for Transcatheter Aortic Valve Replacement was between $5.0 Million and $10.0 Million.

How much is the Mitral Valve Repair Devices segment projected to be worth by 2035?

The Mitral Valve Repair Devices segment is projected to be worth between $4.5 Million and $9.0 Million.

What is the valuation range for Minimally Invasive procedures in 2024?

The valuation range for Minimally Invasive procedures was between $5.0 Million and $10.0 Million.

Which end user segment had the highest valuation in 2024?

The Hospitals segment had the highest valuation, ranging from $8.0 Million to $16.0 Million.

What indications are driving the growth of the structural heart-devices market?

Indications driving growth include Aortic Stenosis, Mitral Regurgitation, and Heart Failure.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions